Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Schlack · SciRah

Researcher profile · Semantic Scholar

K. Schlack

Share profile

K. Schlack — researcher profile on SciRah

h-index: 16
Works: 83
Citations: 1,110

Most-cited papers

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
N. Klümper, D. Ralser, J. Ellinger, F. Roghmann +36 more
2022Clinical Cancer Research195 citations Open access
Semantic Scholar
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
R. Seifert, K. Kessel, K. Schlack, Manuel Weber +9 more
2020European Journal of Nuclear Medicine and Molecular Imaging152 citations Open access
Semantic Scholar
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
N. Klümper, Ngoc Khanh Tran, S. Zschäbitz, Oliver Hahn +37 more
2024Journal of Clinical Oncology100 citations Open access
Semantic Scholar
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617
K. Kessel, R. Seifert, M. Schäfers, M. Weckesser +3 more
2019Theranostics74 citations Open access
Semantic Scholar
Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?
Yvonne Klaile, K. Schlack, M. Boegemann, Julie Steinestel +2 more
2016Translational Andrology and Urology58 citations Open access
Semantic Scholar
Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort
S. Zschäbitz, N. Biernath, T. Hilser, Alexander Höllein +22 more
2023European Urology Open Science49 citations Open access
Semantic Scholar
Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy
R. Seifert, K. Kessel, K. Schlack, M. Weckesser +5 more
2021Theranostics46 citations Open access
Semantic Scholar
Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
R. Seifert, K. Kessel, K. Schlack, M. Weckesser +2 more
2020European Journal of Nuclear Medicine and Molecular Imaging40 citations Open access
Semantic Scholar
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
N. Klümper, D. Ralser, Romina Zarbl, K. Schlack +18 more
2021Journal for ImmunoTherapy of Cancer36 citations Open access
Semantic Scholar
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
M. Boegemann, K. Schlack, Stefan Thomes, Julie Steinestel +5 more
2017International Journal of Molecular Sciences36 citations Open access
Semantic Scholar
Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis
Wolfgang Roll, P. Schindler, Max Masthoff, R. Seifert +5 more
2021Cancers35 citations Open access
Semantic Scholar
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
K. Kessel, R. Seifert, M. Weckesser, Wolfgang Roll +5 more
2020Theranostics35 citations Open access
Semantic Scholar
The safety and efficacy of gemcitabine for the treatment of bladder cancer
K. Schlack, M. Boegemann, Julie Steinestel, A. Schrader +1 more
2016Expert Review of Anticancer Therapy35 citations
Semantic Scholar
Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate
M. Boegemann, K. Schlack, A. Fischer, J. Gerss +4 more
2016PLoS ONE24 citations Open access
Semantic Scholar
Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
Konstantin Seitzer, R. Seifert, K. Kessel, Wolfgang Roll +3 more
2021Cancers21 citations Open access
Semantic Scholar
Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer
Mahmoud Abbas, Barbara Heitplatz, Christof Bernemann, M. Boegemann +4 more
2023Oncology Letters17 citations Open access
Semantic Scholar
Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
Neele Wüstmann, K. Seifert, Verena Humberg, Julia Vieler +9 more
2023Biomarker Research14 citations Open access
Semantic Scholar
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
K. Schlack, K. Seifert, Neele Wüstmann, Verena Humberg +8 more
2022Scientific Reports11 citations Open access
Semantic Scholar
ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis
K. Schlack, L. Krabbe, K. Rahbar, K. Isenberg +3 more
2021Translational Andrology and Urology11 citations Open access
Semantic Scholar
Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry.
M. Boegemann, K. Schlack, M. Rink, S. Bernhardt +5 more
2020Future Oncology11 citations Open access
Semantic Scholar
Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors.
M. Silberg, Laura-Maria Krabbe, M. Bögemann, A. J. Schrader +2 more
2024Clinical Genitourinary Cancer10 citations Open access
Semantic Scholar
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
K. Schlack, L. Krabbe, M. Fobker, A. Schrader +2 more
2016International Journal of Molecular Sciences10 citations Open access
Semantic Scholar
Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [68Ga]Ga-OncoACP3-DOTA.
Philipp Backhaus, S. Cazzamalli, S. Oehler, F. Büther +24 more
2025European Urology9 citations Open access
Semantic Scholar
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry.
A. Strauß, M. Schmid, M. Rink, M. Moran +5 more
2021Future Oncology7 citations Open access
Semantic Scholar
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy.
N. Shore, M. Broder, Pedro C. Barata, T. Crispino +14 more
2024European Urology Oncology6 citations Open access
Semantic Scholar
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review
Annemarie Uhlig, Lothar Bergmann, M. Bögemann, Thomas Fischer +9 more
2024Urologia internationalis6 citations Open access
Semantic Scholar
High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial
Oliver Hommerding, M. Bernhardt, Tobias Kreft, A. Scherping +31 more
2024Virchows Archiv6 citations Open access
Semantic Scholar
Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project
T. Hilser, C. Darr, G. Niegisch, M. Schnabel +10 more
2024Cancers5 citations Open access
Semantic Scholar
Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET
D. Ventura, P. Rassek, P. Schindler, B. Akkurt +7 more
2024Cancer Imaging5 citations Open access
Semantic Scholar
Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer.
N. Klümper, Ngoc Khanh Tran, S. Zschaebitz, Oliver Hahn +14 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting
M. Boegemann, K. Schlack, Lena Früchtenicht, Julie Steinestel +4 more
2019OncoTarget5 citations Open access
Semantic Scholar
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.
N. Klümper, T. Büttner, Sebastian Rauch, S. Zschäbitz +39 more
2026Clinical Cancer Research4 citations Open access
Semantic Scholar
Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group
Hendrik Dinkel, L. Materna, R. Stelmach, S. Zschäbitz +18 more
2025International Journal of Cancer4 citations Open access
Semantic Scholar
Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: First results on outcomes and safety in a German multicenter real-world patient cohort (GUARDIANS).
S. Zschaebitz, J. Casuscelli, T. Büttner, C. Darr +16 more
2025Journal of Clinical Oncology4 citations
Semantic Scholar
Enhancing Biomarker Detection in Cancer: A Comparative Analysis of Pre-analytical Reverse Transcription Enzymes for Liquid Biopsy Application.
Neele Wüstmann, Verena Humberg, Julia Vieler, Konstantin Seitzer +12 more
2024Laboratory investigation; a journal of technical methods and pathology3 citations Open access
Semantic Scholar
The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide
Renata Poteska, K. Rahbar, A. Semjonow, A. Schrader +2 more
2022BMC Cancer3 citations Open access
Semantic Scholar
Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
M. Boegemann, P. Goebell, M. Woike, Johanna Buncke +2 more
2021Translational Andrology and Urology3 citations Open access
Semantic Scholar
Response assessment of patients with locally advanced renal cell carcinoma receiving prior systemic therapy
K. Seifert, Hendrik Dinkel, Linda Huberth, D. Tiedje +10 more
2026BMC Cancer2 citations Open access
Semantic Scholar
Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study
K. Schlack, S. Machtens, T. Kubin, M. Ruhnke +7 more
2025Journal of Cancer Research and Clinical Oncology2 citations Open access
Semantic Scholar
Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
Neele Wüstmann, Julissa Reimann, Julia Vieler, Verena Humberg +4 more
2025Biochimica et biophysica acta. Molecular cell research2 citations Open access
Semantic Scholar
Molecular analysis of androgen receptor splice variant AR-V3 reveals eminent ambiguity regarding activity and clinical utility
Neele Wüstmann, Verena Humberg, Julia Vieler, K. Seifert +4 more
2025Cancer Cell International2 citations Open access
Semantic Scholar
Subgroup analysis of real-world efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial carcinoma from a European database.
C. Darr, N. Klümper, T. Büttner, Nina Holzwarth +16 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.
S. Zschaebitz, N. Klümper, T. Büttner, Nina Holzwarth +16 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Real-world treatment (tx) patterns and clinical outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in Germany: Results of a retrospective observational study (CONVINCE).
S. Machtens, K. Schlack, T. Kubin, M. Ruhnke +7 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry
A. Uhlig, Johannes Uhlig, M. Woike, Thomas Fischer +8 more
2023Kidney Cancer2 citations Open access
Semantic Scholar
Dose escalation of cabozantinib as a viable option for the treatment of mRCC.
M. Boegemann, L. Krabbe, A. Schrader, A. Semjonow +2 more
20182 citations
Semantic Scholar
Early changes in PROSTest, a blood-based mRNA assay, as a predictor of outcomes of 177 LuPSMA radioligand therapy and chemotherapy in metastatic castration-resistant prostate cancer.
K. Rahbar, K. Schlack, M. Boegemann, M. Kidd +1 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study.
Emily Rinderknecht, Gloria Bielstein, R. Cathomas, K. Schlack +13 more
2026Urologic oncology1 citations
Semantic Scholar
Clinical characteristics, treatment patterns, and survival outcomes in ductal prostate cancer: a multicenter retrospective analysis
A. Handke, P. Paffenholz, K. Schlack, K. Seifert +10 more
2026World journal of urology1 citations Open access
Semantic Scholar
Membranous Nectin-4 expression to predict enfortumab vedotin response in metastatic urothelial carcinoma.
N. Klümper, T. Büttner, Sebastian Rauch, S. Zschaebitz +14 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Boegemann×16
Invite
M. Boegemann — researcher profile on SciRah
M. Bögemann×14
Invite
M. Bögemann — researcher profile on SciRah
A. Schrader×13
Invite
A. Schrader — researcher profile on SciRah
C. Darr×11
Invite
C. Darr — researcher profile on SciRah

×11

Invite

K. Rahbar — researcher profile on SciRah

Invite

L. Krabbe — researcher profile on SciRah

Christof Bernemann×9

Invite

Christof Bernemann — researcher profile on SciRah

Julie Steinestel×8

Invite

Julie Steinestel — researcher profile on SciRah

P. Paffenholz×8

Invite

P. Paffenholz — researcher profile on SciRah

F. Zengerling×7

Invite

F. Zengerling — researcher profile on SciRah

Invite

T. Büttner — researcher profile on SciRah

Invite

R. Seifert — researcher profile on SciRah